Compare BioNano Genomics Inc (BNGO) vs Deere & Company (DE) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
BioNano Genomics Inc vs Deere & Company — how do they compare? BioNano Genomics Inc trades at $1.17 (market cap $13.20M), while Deere & Company trades at $580.08 (market cap $157.75B). The key difference: Deere & Company is far larger — about 11950.8× BioNano Genomics Inc's market cap, and Deere & Company pays a 1.11% dividend while BioNano Genomics Inc pays none. Which is the better fit depends on your goals.
| BNGO | DE | |
|---|---|---|
Market Cap | $13.20M | $157.75B |
Sector | Health | Industrials |
52-Week High | $4.92 | $662.49 |
52-Week Low | $1.09 | $439.11 |
Enterprise Value | $15.81M | $212.58B |
Dividend Yield | — | 1.11% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Bionano Genomics (BNGO) trades at $1.17, down 2.5% today, but maintains a bullish technical signal with strong moving average support. The company shows improving fundamentals with revenue stabilizing around $29M annually and narrowing losses, though it remains unprofitable with a -109.95% net margin. Recent positive developments include debt retirement and growing adoption of optical genome mapping technology.
BNGO presents a high-risk, high-reward opportunity with analyst consensus leaning bullish (57% buy ratings). The stock trades at attractive valuation multiples (P/S 0.31, P/B 0.36) but faces execution risks in achieving profitability. Key catalysts include continued technology adoption and potential margin improvement, while persistent losses and competitive pressures remain concerns.
Deere & Company (DE) trades at $585.64, down 0.21% on the day, with a bearish technical signal from moving averages and oscillators. The company has beaten earnings estimates for three consecutive quarters, with Q2 2026 results pending. Revenue declined to $44.67B in 2025, though net income margin remains solid at 10.33%. Recent news highlights a $20B precision agriculture initiative and regulatory agreements enhancing farmer access to repair tools.
The outlook is mixed: analyst consensus targets $676.08 (15% upside) with 41% buy ratings, but technicals and declining revenue pose near-term risks. Key opportunities include margin strength and agtech growth; risks involve cyclical farming demand and high debt levels. Investors should weigh fundamental resilience against sector headwinds.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
About BioNano Genomics Inc
Bionano Genomics Inc is a life sciences instrumentation company in the genome analysis space. It is engaged in the development and marketing of the Saphyr system, a platform for ultra-sensitive and ultra-specific structural variation detection that enables researchers and clinicians to accelerate the search for new diagnostics and therapeutic targets and to streamline the study of changes in chromosomes.
Read more on BNGO →About Deere & Company
Deere is the world's leading manufacturer of agricultural equipment, producing some of the most recognizable machines in the heavy machinery industry. The company is divided into four reportable segments: production and precision agriculture, small agriculture and turf, construction and forestry, and John Deere Capital. Its products are available through an extensive dealer network, which includes over 1,900 dealer locations in North America and approximately 3,700 locations globally. John Deere Capital provides retail financing for machinery to its customers, in addition to wholesale financing for dealers, which increases the likelihood of Deere product sales.
Read more on DE →
